|
 |
|||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Techvest Healthcare Conference Company to give Corporate Presentation on its Cancer and HIV Platforms SAN DIEGO, PRNewswire-FirstCall – October 7, 2003 – ADVENTRX Pharmaceuticals, Inc. (OTC Bulletin Board: AVRX) announced today that its Chief Executive Officer Nicholas J. Virca is scheduled to present on Tuesday, October 21st at 3:40 p.m. at the Rodman & Renshaw Techvest Healthcare Conference which will be held at the Boston Marriott Long Wharf Hotel in Boston, Massachusetts. This is the fifth annual Techvest Healthcare Conference which is expected to draw a record number of attendees. It will bring together life science companies, investors, business development executives and industry leaders in a unique forum to learn more about technology advances in the life sciences area. "We are extremely pleased to have been invited to participate in this conference, which will give us the opportunity to discuss our goals and objectives for ADVENTRX technologies in the arena of cancer and HIV therapeutics and present new information on our clinical trials for our lead cancer drug, CoFactor™ and HIV viral entry inhibitor, BlockAide/CR™", said Mr. Virca, ADVENTRX' Chief Executive Officer. For more complete details on the Rodman & Renshaw Techvest Conference, visit www.adventrx.com and click on Events & Webcasts in the INVESTOR section. About ADVENTRX ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. About RODMAN & RENSHAW Rodman & Renshaw is a privately owned, full-service investment banking and brokerage firm headquartered in New York City, focusing exclusively on emerging growth companies. Currently, the firm has a team of seven Ph.D. level biotech analysts, covering the life sciences sector. The firm announced on July 29, 2003, that through an affiliate, it had purchase all the rights and assets related to the Techvest Healthcare Conferences from Techvest Partners, LLC, as part of its commitment to serving the needs of life sciences companies and investors. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: ADVENTRX Pharmaceuticals, Inc. Nicholas J. Virca, 858/271-9671 Fax: 858/271-9678 Virca@adventrx.com CEOCast, Inc. for ADVENTRX Pharmaceuticals Ken Sgro, 212/732-4300 Fax: 212/732-1131 kensgro@ceocast.com |
